Lisata Agrees to Acquire Marea With $225 Million of New Capital

Company Lisata Therapeutics and Marea Therapeutics Event Type Stock-for-Stock Acquisition With Concurrent Private Placement Platform Cardioendocrine Pipeline (ANGPTL4-Directed and Other Programs) Indication Severe Hypertriglyceridemia; Acromegaly Summary Lisata Therapeutics agreed to acquire privately held Marea Therapeutics in a stock-for-stock transaction accompanied by a $225 million private…